Impact of XDEMVY® on Demodex Blepharitis in Soft Contact Lens Wearers

Inclusion Criteria:

• Be willing to sign the informed consent form and is deemed capable of complying withthe requirements of the study protocol

• Must meet the following criteria in at least one eye: Have more than 10 eyelashes (Grade 2 or higher) with collarettes on the upper or lower eyelid; have at leastGrade 1 erythema of the lower eyelid; and have a total meibomian gland secretionscore ≥ 12 but ≤ 32 AND have a minimum of 6 expressible glands for the 15 glandsevaluated on the lower eyelid

• Currently wearing soft contact lenses on both eyes an average of at least 2 days perweek with an average minimum wearing time of 6 hours each day over the past 3 monthsand is able and willing to continue to wear contact lenses during the study

Exclusion Criteria:

• Use of artificial tears or rewetting drops within 24 hours of the Screening visit orunwilling to forego the use of this treatment during the study

• Prescription AND systemic, drug delivery implant, ocular topical, or topical:antibacterial, anti-parasitic, or anti-inflammatory corticosteroid treatment within 14 days of the Screening or Day 1 visits

• Use of TYRVAYA™ Nasal Spray (varenicline solution, Oyster Point Pharma) within 14days of the Screening visit or unwilling to forego the use of this treatment duringthe study

• Use of XDEMVY™ (lotilaner ophthalmic solution) 0.25%, Tarsus Pharmaceuticals, Inc.,within 12 months of the Screening visit

• Treatment for blepharitis (e.g., tea tree oil-based products, hypochlorousacid-based products, commercial eyelid foams, eyelid wipes, lid scrubs, etc.) within 14 days of the Screening visit or unwilling to forego the use of these treatmentsduring the study

• Use of artificial eyelashes or eyelash extensions at the Screening visit if theylimit accurate eyelid margin assessment

• Currently pregnant or lactating